Cargando…

Analysis of novel enzalutamide-resistant cells: upregulation of testis-specific Y-encoded protein gene promotes the expression of androgen receptor splicing variant 7

BACKGROUND: Enzalutamide, a second-generation antiandrogen, is an approved medicine for the treatment of metastatic castration-resistant prostate cancer (CRPC); however, the mechanisms behind the resistance are not completely understood. In the present study, we established enzalutamide-resistant ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seki, Masanao, Kajiwara, Daisuke, Mizutani, Hiroya, Minamiguchi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798816/ https://www.ncbi.nlm.nih.gov/pubmed/35117234 http://dx.doi.org/10.21037/tcr-20-1463

Ejemplares similares

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
por: Banuelos, Carmen A., et al.
Publicado: (2020)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
por: Hong, Zhe, et al.
Publicado: (2021)

Androgen Receptor Splice Variants Contribute to the Upregulation of DNA Repair in Prostate Cancer
por: Tolkach, Yuri, et al.
Publicado: (2022)

Decoding the androgen receptor splice variants
por: Lu, Changxue, et al.
Publicado: (2013)

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
por: Cochrane, Dawn R, et al.
Publicado: (2014)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Androgen Receptor Splicing Variant-7 in Breast Cancer: Clinical and Pathologic Correlations
por: Ferguson, Donna C., et al.
Publicado: (2022)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

Splice Variants of Androgen Receptor and Prostate Cancer
por: Caffo, Orazio, et al.
Publicado: (2016)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
por: Rosar, Florian, et al.
Publicado: (2022)

Choice of antibody is critical for specific and sensitive detection of androgen receptor splice variant-7 in circulating tumor cells
por: Khan, Tanzila, et al.
Publicado: (2022)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint
por: Yu, Bingbing, et al.
Publicado: (2021)

Role of androgen receptor splice variant 7 (AR-V7) in prostate cancer resistance to 2(nd) generation androgen receptor signaling inhibitors
por: Zhu, Yezi, et al.
Publicado: (2020)

Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells
por: Rana, Manjul, et al.
Publicado: (2021)

Cloning and Characterization of Novel Testis-Specific Diacylglycerol Kinase η Splice Variants 3 and 4
por: Murakami, Eri, et al.
Publicado: (2016)

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
por: Ware, Kathryn E., et al.
Publicado: (2016)

Expression of androgen receptor splice variants in clinical breast cancers
por: Hickey, Theresa E., et al.
Publicado: (2015)

Role of androgen receptor splice variants in prostate cancer metastasis
por: Xu, Jin, et al.
Publicado: (2016)

Tzfp Represses the Androgen Receptor in Mouse Testis
por: Furu, Kari, et al.
Publicado: (2013)

Author Correction: Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells
por: Rana, Manjul, et al.
Publicado: (2021)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
por: Alumkal, Joshi J., et al.
Publicado: (2020)

Androgen receptor splice variant 7 in castration resistant prostate cancer treated with hormonal therapy: what is in the pipeline?
por: Chirra, Martina, et al.
Publicado: (2019)

Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer
por: Sowalsky, Adam G., et al.
Publicado: (2022)

Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy
por: Cao, Bo, et al.
Publicado: (2014)

Androgen receptor splice variants and polycystic ovary syndrome: cause or effect?
por: Walters, Kirsty A, et al.
Publicado: (2016)

Androgen receptor splice variants and prostate cancer: From bench to bedside
por: Wadosky, Kristine M., et al.
Publicado: (2017)

Regulation of androgen receptor splice variant AR3 by PCGEM1
por: Zhang, Ziqiang, et al.
Publicado: (2016)

Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma
por: Song, Huijuan, et al.
Publicado: (2020)

Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy
por: Ouyang, Wei, et al.
Publicado: (2021)

Upregulation of glucocorticoid receptor‐mediated glucose transporter 4 in enzalutamide‐resistant prostate cancer
por: Hoshi, Seiji, et al.
Publicado: (2021)

Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
por: Kattan, Michael W., et al.
Publicado: (2020)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mm9seahsm5stnkeldnh3naj261